Skip to main content

Table 1 The clinical data of CMV retinitis patients with AIDS before ganciclovir therapy and after ganciclovir therapy

From: Prevalence and clinical management of cytomegalovirus retinitis in AIDS patients in shanghai, china

Patient Age Gender CD4 + Mode Other HIV VL Log-HIV CMV- CMV- CMV VL Log-CMV Vision Acuity
ID (years)   Count of OI (copies ml)   IgM IgG (copies/ml)   
    (cells/μl) transmission         
1 (bi) 55 M 157 S TB 1.78 × 103 7.48 Neg Pos 2.37 × 103 7.77 20/25(R), 20/32(L)
2 34 M 4 B PJP 3.60 × 105 12.79 Pos Pos Neg NA 20/32(L)
3 46 F 20 B TB 1.21 × 105 11.7 Neg Pos Neg NA 20/50(L)
4 37 M 6 S OFI,PFI 2.16 × 105 12.28 Neg Pos 6.24 × 103 8.74 20/63(L)
5 (bi) 33 M 53 B PFI 5.11 × 102 6.24 Neg Pos 3.65 × 103 8.20 20/63(R), 20/200(L)
6 34 M 99 B N 1.24 × 103 7.12 Neg Pos 5.75 × 103 8.66 20/250(R)
7 (bi) 42 M 7 S HZ,PJP, 1.71 × 104 9.75 Neg Pos 8.57 × 103 9.06 20/200(R), 20/100(L)
8 52 M 45 U TB 6.10 × 105 13.32 Neg Pos 2.51 × 103 7.83 20/25(R)
9 (bi) 26 M 28 S PC 7.74 × 104 11.26 Neg Pos 1.87 × 104 9.84 20/50(R), 20/50(L)
10 48 M 5 U PJP 1.67 × 104 9.72 Neg Pos 1.23 × 105 11.72 20/50(R)
11 (bi) 25 F 3 S N 1.80 × 105 12.1 Neg Pos Neg NA 20/200(R), 20/20(L)
12 35 M 28 S L,PI 3.87 × 104 10.56 Neg Pos 3.34 × 105 12.72 20/400(L)
13 (bi) 42 M 1 U FI 1.10 × 106 13.91 Neg Pos 1.08 × 105 11.59 20/50(R), HM/BE(L)
14 (bi) 34 M 97 S CM 3.81 × 104 10.55 Neg Pos 8.08 × 103 9.00 20/100(R), HM/BE(L)
15 26 M 36 S N 6.55 × 105 13.39 Neg Pos 2.04 × 103 7.62 HM/BE(L)
16 (bi) 25 M 5 S CMVM 2.56 × 104 10.15 Neg Pos 3.86 × 103 8.26 LP (bi)
17 (bi) 33 F 3 S CNSI 4.91 × 104 10.8 Neg Pos 3.37 × 104 10.43 20/63(R), 20/100(L)
18 73 F 17 S PJP 6.64 × 105 13.41 Neg Pos 1.31 × 103 7.18 20/200(L)
19 (bi) 59 M 16 S PJP 1.89 × 105 12.15 Neg Pos 6.50 × 106 15.69 20/200(R), 20/100(L)
20 (bi) 42 M 33 S FI 2.06 × 103 7.63 Neg Pos 1.69 × 106 14.34 20/200(R), HM/BE(L)
21 30 M 0 S PJP 2.73 × 105 12.52 Neg Pos 3.64 × 105 12.80 HM/BE(R)
22 (bi) 73 M 35 S PJP 6.64 × 105 13.41 Neg Pos 2.03 × 105 12.22 NA
23 59 M 30 S TB 2.50 × 104 10.13 Neg Pos 1.78 × 105 12.09 20/40(R)
Patient Time Time response to anti-CMV treatment/ CMV VL CD 4 + Counts* Vision Acuity*
ID HAART Received Anti-CMV Received treatment complications (copies/ml) (cells/μl)     
  (weeks) (weeks)          
1 (bi) 72 4 Effective NO Neg 235 20/20(R), 20/20(L)
2 24 24 Effective NO Neg 58 20/20(L)
3 28 24 Effective NO Neg 248 20/20(L)
4 16 8 Effective IRU Neg 165 20/32(L)
5 (bi) 40 28 Effective NO Neg 227 20/20(R), 20/25(L)
6 24 24 Effective NO Neg 400 20/20(R)
7 (bi) 4 3 Effective IRU Neg 186 20/20(R), 20/20(L)
8 4 2 Effective NO Neg 460 20/20(R)
9 (bi) 12 6 Effective NO Neg 177 20/32(R), 20/32(L)
10 8 2 Effective NO Neg 166 20/32(R)
11 (bi) 8 8 Effective NO Neg 120 20/20(R), 20/20(L)
12 28 2 Effective NO Neg 121 20/32(L)
13 (bi) 20 2 Effective NO Neg 189 20/25(R), 20/400(L)
14 (bi) 12 12 Effective NO Neg Missing 20/32(R),CF/50 cm(L)
15 24 16 Effective Rel, RD Neg 182 20/50(L)
16 (bi) 20 8 Effective NO Neg 222 HM/BE(R),CF/BE(L)
17 (bi) 0* 0* NA NA NA NA NA
18 0* 0* NA NA NA NA NA
19 (bi) 2 1.3 NA NA NA NA NA
20 (bi) 6 0* NA NA NA NA NA
21 8 0* NA NA NA NA NA
22 (bi) 0* 0* NA NA NA NA NA
23 0* 0* NA NA NA NA NA
  1. CD4 + count: CD4 + count when diagnosed CMV retinitis; CD4 + count*: CD4 + count when follow-up finished; Vision Acuity: vision acuity when diagnosed CMV retinitis; Vision Acuity*: vision acuity when follow-up finished; HM/BE: hand movement/before eye; LP: light perception; NA: not available; bi: bilatéral; HIV VL: HIV viral load; CMV VL: CMV viral load; F: female; M: male; S: sexually transmission; B: blood infusion; U: unknown; Other OI: other opportunistic infection; TB: tuberculosis; PJP: pneumocystis jiroveci pneumonia; OFI: oral fungal infection; PFI: pulmonary fungal infection; N: no other opportunistic infection but CMV retinitis; HZ: herpes zoster; PC: pancreatitis; L: lymphoma; PI: pulmonary infection; FI: fungal infection; CM: cryptococcal meningitis; CMVM: CMV myelitis; CNSI: central nervous system infection; Time ART received: the time of ART from beginning ART to ending the follow-up; Time Anti-CMV received: the time during anti-CMV treatment with ganciclovir; bi: bilateral; HIV VL: HIV viral load; CMV VL: CMV viral load; Log-HIV: Log-transform of HIV viral load; Log-CMV: Log-transform of CMV viral load; CF/50 cm: count finger/50 cm; HM/BE: hand movement/before eye; CF/BE: count finger/before eye; NA: not available; 0* indicated that the therapeutic regime was not started or less than one week and the patients were died shortly after admitted to the hospital; Rel: relapse; RD: retinal detachment; NO: no ocular complications